Two Doses of Recombinant Zoster Vaccine Worked Well in People 50 and Older

Vaccine efficacy in people aged ≥50 was 74% for herpes zoster and 84% for post-herpetic neuralgia, protection that persisted throughout 4 years.

In prelicensing studies, the adjuvanted recombinant zoster vaccine (RZV) was shown to be highly effective in preventing both herpes zoster (HZ) and post-herpetic neuralgia (PHN). Because longer-term data have been lacking, investigators at Kaiser Permanente Southern California (KPSC) evaluated vaccine effectiveness (VE) of RZV in patients aged ≥50 years from mid-2018 through late 2022.

Among almost 103,000 persons who received two doses of RZV (the second dose 4 weeks to 6 months after the first), VE for preventing HZ was 74% compared to a matched unvaccinated cohort. Rates were 62% in immunocompromised patients. VE for preventing PHN was 84%, dropping to 45% in immunocompromised patients. After 4 years, VE remained stable at 73% (HZ) and 87…

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Two Doses of Recombinant Zoster Vaccine Worked Well in People 50 and Older

Topics

Reviewing Author